AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

The FluMist vaccine, manufactured by AstraZeneca, had previously been approved back in 2003 to be given by health care ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first ...

The FDA has started a review of an extension to the labelling for AstraZeneca’s influenza ... FluMist could become the first self-administered flu vaccine in the US, opening up a new avenue ...

More than one in two Irish parents say their child missed schools days in the past year due to flu or flu-like symptoms with ...

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of ...

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the ...

has approved the first nasal spray flu vaccine which can be administered by the patient or a caregiver. FluMist, produced by European pharmaceutical company and Covid vaccine-maker AstraZeneca ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007 ... FluMist is officially the first ...